25 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22703 | Stage III or IV, unresecable | Joseph Kerger | Skin | BMS - Bristol Myers Squibb int. | CA045-001 | Trial closed | A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma | joseph.kerger@hubruxelles.be | 3 | 3 | |
| 22707 | Complete resection | Joseph Kerger | Skin | BMS - Bristol Myers Squibb int. | CA209-8RX | Trial open for recruitment | A national, prospective, Therapeutic Non-Interventional Clinical Trial (TNICT) in patients receiving adjuvant nivolumab therapy for resected melanoma | joseph.kerger@hubruxelles.be | 4 | 4 | |
| 22758 | ECOG 0 or 1 | Ahmad Hussein Awada | Multiple | BMS - Bristol Myers Squibb int. | CA209358 | Trial closed | Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
| 22821 | BRAF V600 mutation | Joseph Kerger | Skin | Roche | COBRIM | Trial closed for recruitment | GO28141 A phase III, double-blind, placebo-controlled study of Vemurafenib versus Vemurafenib plus GDC-0973 in previously untreated BRAFV600-mutation positive patients with unresectable locally Advanced or metastatic melanoma | joseph.kerger@hubruxelles.be | 3 | 3 | |
| 22820 | N-Ras mutated | Joseph Kerger | Skin | Merck Serono | EMR 200066-007 | Trial closed | A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with NRas mutated locally advanced or metastatic malignant cutaneous melanoma | joseph.kerger@hubruxelles.be | 2 | 2 | |
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 29330 | Annie Drowart | Skin | EORTC | EORTC-2139-MG - COLUMBUS-AD | Trial closed for recruitment | Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group | Annie.Drowart@hubruxelles.be | 3 | 3 | ||
| 22798 | Relasped/refractory patient | Christiane Jungels | Multiple | Imcheck | EVICTION | Trial open for recruitment | A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22764 | any line | Ahmad Hussein Awada | Multiple | Genentech-Roche | GO29674 | Trial closed | A Phase Ib, Open-Label, Dose-escalation Study of the safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22754 | Brain metastasis | Ahmad Hussein Awada | Multiple | Lilly | I3Y-MC-JPBO | Trial closed | A phase II study of Abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer, non-small cell lung cancer, or melanoma | ahmad.awada@hubruxelles.be | 2 | 2 | |
| 22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22650 | vaccine, diarrhea, clostridium | Multiple | Pfizer | IJB_2672 | Trial closed | A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | 3 | 3 |